Table 5.
Baseline, post (6 or 12 weeks) and change data after placebo or SXRG treatment (Study 2) for blood pressure and weight.
| AA Baseline to 6 Weeks (Placebo) n = 30 |
AB Baseline to 12 Weeks (Placebo then Active) n = 30 |
BB Baseline to 6 Weeks (Active) n = 34 |
BA Baseline to 12 Weeks (Active then Placebo) n = 34 |
p-Value * | |
|---|---|---|---|---|---|
| Gender, F (%) | 15 (50%) | 15 (50%) | 18 (53%) | 18 (53%) | 0.814 |
| Age | 51.7 ± 15 | 51.7 ± 15 | 52.2 ± 11 | 52.2 ± 11 | 0.887 |
| BMI (kg/m2) | |||||
| Baseline § | 28 (26, 31) | 28. (26, 31) | 29 (27, 31) | 29 (27, 31) | 0.101 |
| Post | 29 (26, 31) | 29 (26, 31) | 29 (28, 31) | 29 (27, 31) | 0.363 |
| Change | 0 (0, 1) | 0 (0, 0) | 0 (0, 0) | 0 (−1, 0) | |
| Waist Circumference (cm) | |||||
| Baseline | 95 (85, 104) | 95 (85, 104) | 96 (92, 105) | 96 (92, 105) | 0.257 |
| Post | 97 (85, 106) | 99 (87, 107) | 100 (93, 106) | 99 (92, 107) | 0.660 |
| Change | 1 (−1, 4) | 2 (−1, 5) | 3 (−1, 5) | 1 (−3, 4) | |
| Systolic BP (mmHg) | |||||
| Baseline § | 132 (117, 142) | 132 (117, 142) | 130 (122, 139) | 130 (122, 139) | 0.850 |
| Post | 127 (114, 141) | 122 (114, 139) | 129 (119, 135) | 125 (114, 136) | 0.809 |
| Change | −5.0 (−10.8, 1.8) | −6.0 (−13.5, 1.0) | −4.0 (−14.5, 4.8) | −6.0 (−16.3, 0.5) | |
| Diastolic BP (mmHg) | |||||
| Baseline | 82 (71, 89) | 82 (71, 89) | 83 (75, 94) | 83 (75, 94) | 0.524 |
| Post | 79 (72, 87) | 76 (70, 85) | 80 (73, 87) | 79 (67, 87) | 0.653 |
| Change | −1.5 (−8.0, 2.8) | −4.0 (−8.0, 3.0) | −4.0 (−8.0, 4.0) | −3.0 (−10.8, 1.0) |
Data are presented as number and % for gender, mean ± standard deviation or median (25th and 75th percentile). AA = Placebo for 6 weeks; AB = Placebo for 6 weeks then SXRG treatment for 6 weeks; BB = SXRG treatment for 6 weeks; BA = SXRG treatment for 6 weeks then placebo for 6 weeks. Change determined by median post value (6 or 12 weeks) minus median baseline value. * p-value at baseline determined by T-test on normal or log-transformed (§) data between the two baseline regime groups. p-value for post measure determined by ANCOVA using absolute data from 6 weeks (for placebo and active group) and 12 weeks (for placebo then active group and active then placebo group) using baseline data as a covariate.